Ultimovacs Announces Further Positive Topline Results from Phase I UV1 Cancer Vaccine Combination Study in Metastatic Melanoma

12 Aug Stock Analysis

Cohort 2 showed 60% objective response rate, 30% complete response rate
90% overall survival rate at 12 months follow-up
Cohort 2 results reinforce results seen in cohort 1
Good safety and tolerability profile supports use of UV1 in combination treatments
…